Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial-Reference-Cited by-同舟云学术

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

Published:2011-07 Issue:7 Volume:12 Page:631-641
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gnant Michael,Mlineritsch Brigitte,Stoeger Herbert,Luschin-Ebengreuth Gero,Heck Dietmar,Menzel Christian,Jakesz Raimund,Seifert Michael,Hubalek Michael,Pristauz Gunda,Bauernhofer Thomas,Eidtmann Holger,Eiermann Wolfgang,Steger Guenther,Kwasny Werner,Dubsky Peter,Hochreiner Gerhard,Forsthuber Ernst-Pius,Fesl Christian,Greil Richard

Publisher

Elsevier BV

Subject

Oncology

Reference44 articles.

1. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials;Gnant;Curr Cancer Drug Targets,2009

2. Exploring the anti-tumour activity of bisphosphonates in early breast cancer;Winter;Cancer Treat Rev,2008

3. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study;Eidtmann;Ann Oncol,2010

4. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST;Coleman;Cancer Res,2009

5. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). 33rd Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 8–12, 2010. Abstr S4–5.

Cited by 422 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer;Breast Cancer Research and Treatment;2024-07-31

2. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies;European Journal of Endocrinology;2024-07-26

3. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw;Supportive Care in Cancer;2024-07-25

4. Tumor‐associated macrophages: A sentinel of innate immune system in tumor microenvironment gone haywire;Cell Biology International;2024-07-25

5. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-07-09